Accepted Manuscript



Just so stories: The random acts of anti-cancer nanomedicine performance

S. Moein Moghimi PhD, Z. Shadi Farhangrazi PhD

PII: S1549-9634(14)00213-5
DOI: doi: 10.1016/j.nano.2014.04.011
Reference: NANO 939

To appear in: *Nanomedicine: Nanotechnology, Biology, and Medicine*

Received date: 31 March 2014
Revised date: 28 April 2014
Accepted date: 29 April 2014

Please cite this article as: Moghimi S. Moein, Farhangrazi Z. Shadi, Just so stories: The random acts of anti-cancer nanomedicine performance, *Nanomedicine: Nanotechnology, Biology, and Medicine* (2014), doi: 10.1016/j.nano.2014.04.011

Just So Stories:
The Random Acts of Anti-Cancer Nanomedicine Performance

S. Moein Moghimi, PhD[a,b*], Z. Shadi Farhangrazi, PhD[c]

[a]Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark

[b]NanoScience Centre, Faculty of Science, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark

[c]Biotrends International, Denver Technological Center, Greenwood Village, Colorado, USA

ABSTRACT: Contrary to high expectations, the majority of clinically approved anti-cancer nanomedicine, and those under clinical trials, have shown limited therapeutic efficacy in humans. So, why these nanomedicine are not delivering their promise? Here, we discuss likely factors, and call for a paradigm shift in approach and design of future cancer nanotherapeutics based on realistic cancer models representing human disease, and better understanding of integrated pathophysiological processes, including systems immunology, that modulate human tumor functionality and growth.

Keywords: Cancer; Complement system; Enhanced permeability and retention; Nanomedicine; Spontaneous tumors; Systems immunology; Xenografts

Number of words (Abstract):	76
Number of words (excluding Abstract):	3331
Reference:	52
Tables:	0
Figures:	1

SMM acknowledges financial support by the Danish Agency for Science, Technology and Innovation, references 09-065736 (Det Strategiske Forskningsråd), and 12-126893 (Technology and Production).

*Correspondence: S.M. Moghimi; Tel.: +35 35336528; E-mail: moien.moghimi@sund.ku.dk

In memory of our friend, Max.